BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Study sponsor: Eikon Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-01Actual
Enrollment · participants1Actual
Source updated2025-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.